-- Presentations to be webcast on www.exelixis.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 1, 2017--
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s President and Chief Executive Officer, will provide
an overview of the company at the following two investor conferences in
Cowen Group 37th Annual Health Care Conference: Exelixis’
presentation is scheduled for 10:40 AM EST / 7:40 AM PST on Tuesday,
March 7, 2017 in Boston.
Barclays Capital Global Healthcare Conference: Exelixis is scheduled
to present at 2:05 PM EDT / 11:05 AM PDT on Tuesday, March 14, 2017 in
Each presentation will be webcast live and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
Please connect to the company’s website at least 15 minutes prior to
each presentation to ensure adequate time for any software download that
may be required to listen to the webcast. Replays will also be available
at the same location for 14 days following each presentation.
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed
to the discovery, development and commercialization of new medicines to
improve care and outcomes for people with cancer. Since its founding in
1994, three products discovered at Exelixis have progressed through
clinical development, received regulatory approval, and entered the
marketplace. Two are derived from cabozantinib, an inhibitor of multiple
tyrosine kinases including MET, AXL and VEGF receptors: CABOMETYX™
tablets approved for previously treated advanced kidney cancer and
COMETRIQ® capsules approved for progressive, metastatic
medullary thyroid cancer. The third product, Cotellic®, is a
formulation of cobimetinib, a selective inhibitor of MEK, is marketed
under a collaboration with Genentech (a member of the Roche Group), and
is approved as part of a combination regimen to treat advanced melanoma.
Both cabozantinib and cobimetinib have shown potential in a variety of
forms of cancer and are the subjects of broad clinical development
programs. For more information on Exelixis, please visit www.exelixis.com
or follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered
U.S. trademarks, and CABOMETYX is a U.S. trademark.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170301006445/en/
Source: Exelixis, Inc.
Susan Hubbard, 650-837-8194
President, Public Affairs and Investor Relations
For Exelixis, Inc.
Hal Mackins, 415-994-0040